JG
PRQR icon

Jefferies Group’s ProQR Therapeutics PRQR Stock Holding History

Jefferies Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,375
Closed -$10.3K – 1788
2022
Q1 		$10.3K Buy
+11,375
New +$38.1K ﹤0.01% 1466
2019
Q1 		– Sell
-40,000
Closed -$631K – 2566
2018
Q4 		$631K Buy
+40,000
New +$734K 0.01% 1372

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jefferies Group's PRQR Position: Q2 2022 in Review

Jefferies Group sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 11,375 shares — an estimated $10.3K sold.

Jefferies Group first reported a position in PRQR in Q4 2018 and held it in 2 quarters. The position peaked at $631K in Q4 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

  • Jefferies Group reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 11,375 ProQR Therapeutics shares in Q2 2022, an estimated $10.3K.
  • Jefferies Group first reported a position in ProQR Therapeutics in Q4 2018 and held it in 2 quarters.
  • Jefferies Group's ProQR Therapeutics position peaked at $631K in Q4 2018.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.